UK Clinical Trial Set-Up Times Drop to 100 Days as Government Meets Target

What was announced

The Department of Health and Social Care and the Office for Life Sciences announced that clinical trial set-up times in the UK fell by 35%.

According to new government data, the average time required to set up a commercial clinical trial dropped to 100 days in the three months to March 2026. That is down from 153 days during the same period in 2025. All 24 commercial trials launched in those three months began within 150 days, beating the 95% target established in the government's Life Sciences Sector Plan.

In addition, every study reviewed by the Medicines and Healthcare products Regulatory Agency and research ethics committees in September 2026 received joint approval within 60 days. The update highlighted several specific projects:

• The BEATRIX study, testing a vaccine for pregnant women, set up in under 150 days.
• The CHILL study screened its first patient 113 days after entering set-up.
• Moderna's Nova 301 study enrolled 2,500 participants within nine weeks.

What it means

Sponsors who finance medical studies face shorter bureaucratic wait times before opening research in the NHS. The National Institute for Health and Care Research provides single-entry support through its Industry Hub and a network of delivery centres.

Patients with serious conditions, including cancer and heart disease, can enter clinical studies sooner when trials launch faster. Earlier site activation allows hospitals to identify volunteers and begin testing experimental drugs without months of administrative delay. The government also plans to support this system with a Health Data Research Service, backed by up to £600 million from public funds and the Wellcome Trust to link NHS records for research.

What the announcement does not tell us

The announcement leaves several practical details unaddressed:

• The 100-day figure reflects only 24 commercial trials across a three-month window. The government did not provide setup times for non-commercial academic research.
• The release does not show whether total patient sign-ups rose. Industry figures from the Association of the British Pharmaceutical Industry noted that patient recruitment has faced consecutive years of decline.
• Ministers did not explain the specific details of the Prime Minister's four steps for brain cancer research.
• The document does not specify how the £600 million data budget is divided between taxpayers and the Wellcome Trust, or when the planned cancer trials accelerator will open.